Thermo Fisher Scientific Ion Torrent Oncomine Myeloid Assay GX v2

Thermo Fisher Scientific has released the Ion Torrent Oncomine Myeloid Assay GX v2, a next-generation sequencing assay that allows researchers to gather comprehensive mutational results from myeloid samples in a single day using the company's Ion Torrent Genexus System.

The Oncomine Myeloid Assay GX v2 offers a comprehensive panel to profile key biomarkers for all major myeloid disorders. It's optimized to detect a wide range of variants, including challenging-to-sequence targets such as FLT3-ITD, CALR, and CEBPA, Thermo Fisher said. The updates for this version of the assay include additional DNA and RNA targets, improved sequencing of key GC-rich regions, and the ability to run the RNA and DNA panels separately. 

The assay also features an automated workflow, enabling samples to be processed from specimen to report with only 20 minutes of hands-on time for technicians and minimal user intervention; an expanded panel with simultaneous profiling of 45 genes and 30 fusion drivers covering more than 700 unique fusions; full specimen coverage, including whole blood, peripheral blood lymphocytes, and bone marrow; and integrated reporting, with annotated variant reports and the latest relevant evidence from public data sources.